These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14656616)

  • 1. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
    Goldie SJ; Paltiel AD; Weinstein MC; Losina E; Seage GR; Kimmel AD; Walensky RP; Sax PE; Freedberg KA
    Am J Med; 2003 Dec; 115(8):632-41. PubMed ID: 14656616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Munakata J; Benner JS; Becker S; Dezii CM; Hazard EH; Tierce JC
    Med Care; 2006 Oct; 44(10):893-9. PubMed ID: 17001259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
    Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
    Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
    Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
    J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.
    Bendavid E; Young SD; Katzenstein DA; Bayoumi AM; Sanders GD; Owens DK
    Arch Intern Med; 2008 Sep; 168(17):1910-8. PubMed ID: 18809819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
    N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost of HIV medication adherence support interventions: results of a cross-site evaluation.
    Schackman BR; Finkelstein R; Neukermans CP; Lewis L; Eldred L;
    AIDS Care; 2005 Nov; 17(8):927-37. PubMed ID: 16265786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.
    Yazdanpanah Y; Goldie SJ; Losina E; Weinstein MC; Lebrun T; Paltiel AD; Seage GR; Leblanc G; Ajana F; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Antivir Ther; 2002 Dec; 7(4):257-66. PubMed ID: 12553480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic viability of antiretroviral adherence interventions.
    Bozzette SA; Gifford AL
    Am J Med; 2003 Dec; 115(8):672-3. PubMed ID: 14656623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.